Prostate, Phase III
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Volunteers
Health Professionals
What is the purpose of this trial?
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Alison Johnson
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- D. Barry Boyd, MD, MS
- Daniel P. Petrylak, MD
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Karishma Mehra, MBBS
- Kayla Martello
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Lynn Mastrianni
- M. Sung Lee, MD
- Madeleine Wood
- Michael Grant, MD
- Michael Hurwitz, MD, PhD
- Michelle Laspino
- Neal Fischbach, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Renee Moye
- Robert Matera, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sharynn Hall, MD, PhD
- Stacey LaRosa
- Su Hsien Lim, MD
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated11/14/2024
- Study HIC#2000036874